ReviewCurrent atherosclerosis reports2022
The Role of High-Density Lipoprotein Cholesterol in 2022.
Review in Current atherosclerosis reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Full-fat yogurt compared with non-fat yogurt reduces blood triacylglycerol concentrations and lowers the triacylglycerol content in specific lipoprotein subclasses in adults with prediabetes: an exploratory analysis of a randomized-controlled trial.Lipids in health and disease · 2025Trial
- Extra virgin olive oil improves HDL lipid fraction but not HDL-mediated cholesterol efflux capacity: a double-blind, randomised, controlled, cross-over study (OLIVAUS).The British journal of nutrition · 2023Trial
- The monocyte-to-HDL cholesterol ratio (MHR) modifies the association between dietary patterns and depression: a sex-specific analysis.European archives of psychiatry and clinical neuroscience · 2026Article
- Dietary Ewe's Yogurt Intake Selectively Modulates HDL Subfractions Without Altering LDL Particle Size in Women: A Six-Week Intervention Study.Nutrients · 2026Article
- Predicting short-term composite outcome risk in heart failure patients using a machine learning model incorporating UHR: a retrospective cohort study.Frontiers in nutrition · 2026Article
- Effect of Calafate (Journal of nutrition and metabolism · 2026Article
- Exploring the role of gelsolin and high-density lipoproteins in autoimmune diseases: spotlight on rheumatoid arthritis and systemic lupus erythematosus.Oxford open immunology · 2026Review
- The neutrophil to high-density lipoprotein cholesterol ratio is associated with disease severity in hypertriglyceridemic acute pancreatitis.BMC gastroenterology · 2025Article
- Interactive effects of high-density lipoprotein cholesterol and insulin resistance on depression: results from the NHANES (2005-2018).Lipids in health and disease · 2025Article
- Investigating the relationship between blood factors and HDL-C levels in the bloodstream using machine learning methods.Journal of health, population, and nutrition · 2025Article
- Investigation of Dyslipidemia and Lipid Profile Ratios Among Patients in Tertiary Care Hospitals.EJIFCC · 2025Article
- A preliminary exploration of a predictive model and nomogram for the efficacy of compound digestive enzyme therapy based on serum (PGI, PGII, VIP, and PRDX1) in patients with functional dyspepsia.BMC gastroenterology · 2025Article
- Causal relationships between four types of lipids and breast cancer risk with potential mediators: evidence from Mendelian randomization study and bioinformatics analysis.Discover oncology · 2025Article
- Research progress on cholesterol metabolism and tumor therapy.Discover oncology · 2025Review
- The association between Glycated Hemoglobin to High Density Lipoprotein Cholesterol Ratio and risk of cardiovascular diseases caused death among adult cancer survivors: evidence from NHANES 1999-2018.Lipids in health and disease · 2025Article
- Investigating Causal Links between Metabolite Profiles and Ulcerative Colitis: A Bidirectional Mendelian Randomization Study.Journal of medical signals and sensors · 2025Article
- Exploring the nonlinear relationship between serum uric acid to high-density lipoprotein cholesterol ratio and obesity in older adults: a cross-sectional study.Frontiers in public health · 2025Article
- Exploring the Association Between Systemic Lupus Erythematosus and High-Density Lipoproteins: A Systematic Review and Meta-Analysis.ACR open rheumatology · 2024Review
- Increased high-density lipoprotein cholesterol in patients with type 2 diabetes and its correlates: a cross-sectional, matched case-control survey.European journal of medical research · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewHigh-density lipoproteins (HDL) are responsible for the transport in plasma of a large fraction of circulating lipids, in part from tissue mobilization. The evaluation of HDL-associated cholesterol (HDL-C) has provided a standard method for assessing cardiovascular (CV) risk, as supported by many contributions on the mechanism of this arterial benefit. The present review article will attempt to investigate novel findings on the role and mechanism of HDL in CV risk determination. RECENT
findingsThe most recent research has been aimed to the understanding of how a raised functional capacity of HDL, rather than elevated levels per se, may be responsible for the postulated CV protection. Markedly elevated HDL-C levels appear instead to be associated to a raised coronary risk, indicative of a U-shaped relationship. While HDL-C reduction is definitely related to a raised CV risk, HDL-C elevations may be linked to non-vascular diseases, such as age-related macular disease. The description of anti-inflammatory, anti-oxidative and anti-infectious properties has indicated potential newer areas for diagnostic and therapeutic approaches. In the last two decades inconclusive data have arisen from clinical trials attempting to increase HDL-C pharmacologically or by way of recombinant protein infusions (most frequently with the mutant A-I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.